16 September 2026 editorial review · Trial
Denosumab for beta-cell function in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Replaced vague early-T1D label with actual1–5year duration, sex-specific minimum age and C-peptide entry criteria; named actual safety/efficacy endpoints.
Registry: NCT06524960. Registered endpoint checked: Primary safety endpoint (up to 12 months); Primary efficacy endpoint (up to 12 months). Eligibility check: Registry age 18 Years to 50 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.